Semaglutide results at 12 weeks: what clinical evidence actually shows

What the STEP 1 trial data says, and why 12 weeks sits inside the titration window

The most robust evidence for semaglutide 2.4mg comes from the STEP 1 trial, published in the New England Journal of Medicine: 1,961 adults with obesity or overweight and at least one weight-related condition, randomised to semaglutide 2.4mg or placebo alongside lifestyle intervention for 68 weeks. Average weight loss at trial end was around 15% of body weight in the semaglutide group, a figure that took the full study period to reach.

At the 12-week mark, participants in STEP 1 were still titrating upwards. The standard schedule moves from 0.25mg (weeks 1–4) through 0.5mg, 1.0mg and 1.7mg before reaching 2.4mg, with roughly four weeks at each level. That means week 12 typically lands somewhere around the 1.0mg dose. Weight loss at this point is real but modest, the medicine is doing the early work of reducing appetite and slowing gastric emptying, but the full pharmacological effect of the maintenance dose hasn't yet been established.

Published data from STEP 1 weight-loss curves show roughly 5–7% mean reduction by around the 16-week point, accelerating as the dose climbs. At 12 weeks specifically, many participants had achieved somewhere in the 3–5% range, an average that conceals wide individual variation. Some people notice more, some notice less. Neither outcome at 12 weeks is a reliable predictor of where you'll be at six or twelve months.

Why individual 12-week results vary as much as they do

A question our prescribers hear most weeks: 'I've lost less than my friend on the same dose, is something wrong?' The answer is almost always no. Several factors shape early response: how quickly a person tolerates dose increases (those who need an extra four weeks at a lower dose to manage nausea will naturally be on a lower dose at week 12); baseline metabolic rate; adherence to the reduced-calorie approach that the licence specifies alongside treatment; and individual differences in gut-hormone sensitivity. Semaglutide works by activating GLP-1 receptors, increasing satiety signals and slowing the rate at which the stomach empties, but people respond to that signal with different intensity.

Gastrointestinal side effects are most noticeable during early titration. Nausea, loose stools and reduced appetite tend to peak after a dose increase and settle over one to two weeks. For some people, managing those effects means the dose progresses more slowly, which in turn means week 12 results sit lower on the curve. That is not a treatment failure; it is the titration doing its job. The NHS medicines page for semaglutide covers what to expect as you move through the dose schedule.

If you are curious about how weight change typically builds across earlier timepoints, the pattern from week 8 onwards shows a clearer upward trend as doses increase, and how long Wegovy takes to work covers the full timeline in detail.

The six-month checkpoint that NICE uses, and what it means for you

NICE's recommendation for semaglutide (Wegovy) includes a clear stopping rule: if a person has lost less than 5% of their body weight after six months at the maintenance dose, continuing treatment should be reviewed. That threshold is measured from the maintenance dose, not from day one of treatment. So for most people the relevant clock doesn't start until they've been on 2.4mg for a sustained period, often not until month four or five of treatment overall.

This is worth knowing at 12 weeks because it reframes the expectation. Three months in, you are usually still climbing the dose ladder. The six-month NICE checkpoint is not measuring your week-12 position; it is measuring the response to full-strength treatment. If you want to understand where results at six weeks or at four weeks typically sit, those pages cover the earlier picture.

For a broader view of how Wegovy fits within the licensed weight-management options available in the UK, the Wegovy overview covers eligibility, the dose schedule and what to expect across the full treatment course. And if you are weighing up how to access treatment safely, where to get Wegovy in the UK explains the legal prescription route and what to look for in a regulated pharmacy.

What a realistic 12-week outcome looks like, and when to speak to your prescriber

A reasonable working expectation at week 12, based on trial data and the titration schedule: somewhere between 2% and 6% body-weight reduction, with most people landing around 3–5% if titration has gone smoothly. That equates to roughly 2–5 kg for someone starting at 90 kg, meaningful, but not the headline number Wegovy eventually produces at full dose.

Three things are worth monitoring at this stage. First, whether gastrointestinal side effects are settling, persistent severe nausea or vomiting at the current dose is a reason to talk to your prescriber before the next increase. Second, whether any changes in mood have emerged, since your prescriber should know about this. Third, general progress with the lifestyle component: the trial evidence comes from participants following dietary guidance alongside the medicine, and the two work together.

If you are considering starting treatment or want a clinical review of your progress, starting a free consultation with our prescribers is the right next step. Every assessment at nume is reviewed by a GPhC-registered Independent Prescriber on the day it is submitted, a real clinician, not an automated system, reads your answers before any treatment decision is made.